The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
CAR-T landscape is witnessing much awaited FDA approvals. Newer therapeutic applications continue to emerge at a rapid pace. Having established the scientific foundation, the question of affordability becomes the next challenge that the industry must overcome. The presentation discusses end-to-end, fully automated, closed manufacturing as the key strategy towards a more affordable CAR-T drug product. The presentation includes a discussion of the following:
Contributors to COGs including raw material and labor.
Focus on three manufacturing related contributors: facility, labor and raw material
Cost reduction approaches for manufacturing and facility solutions
The advancement in technologies and innovative thinking are profoundly changing biopharmaceutical drug production industry holistically, giving rise to “the factory of the future…
In the face of persistent global challenges posed by microbial and viral pathogens, adapting vaccine production to emerging threats demands a shift towards flexible and platform-oriented approaches. An innovative solution is the use of low-energy electron irradiation (LEEI) in liquid suspensions…
With the new Annex 1 being effective since August 25, 2023, the industry needs to be compliant to these requirements. One big topic of the Annex 1 is the Contamination Control Strategy (CCS) which shall bring all control measures together…